ATE509949T1 - Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungen - Google Patents
Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungenInfo
- Publication number
- ATE509949T1 ATE509949T1 AT07856330T AT07856330T ATE509949T1 AT E509949 T1 ATE509949 T1 AT E509949T1 AT 07856330 T AT07856330 T AT 07856330T AT 07856330 T AT07856330 T AT 07856330T AT E509949 T1 ATE509949 T1 AT E509949T1
- Authority
- AT
- Austria
- Prior art keywords
- diagnostic
- metastasically
- therapeutic applications
- specific peptides
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 206010027457 Metastases to liver Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000852A ITTO20060852A1 (it) | 2006-11-30 | 2006-11-30 | Peptidi metastasi-specifici e loro applicazioni diagnostiche e terapeutiche |
| PCT/EP2007/010428 WO2008064910A2 (en) | 2006-11-30 | 2007-11-30 | Metastasis-specific peptides and their diagnostic and therapeutic applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE509949T1 true ATE509949T1 (de) | 2011-06-15 |
Family
ID=39313019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT07856330T ATE509949T1 (de) | 2006-11-30 | 2007-11-30 | Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungen |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8779092B2 (de) |
| EP (1) | EP2121742B1 (de) |
| JP (1) | JP2010510785A (de) |
| AT (1) | ATE509949T1 (de) |
| AU (1) | AU2007324808B2 (de) |
| CA (1) | CA2670532A1 (de) |
| ES (1) | ES2363044T3 (de) |
| IT (1) | ITTO20060852A1 (de) |
| WO (1) | WO2008064910A2 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| CA2638823A1 (en) | 2006-02-13 | 2007-08-23 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| GB0708864D0 (en) * | 2007-05-08 | 2007-06-13 | Molmed Spa | Cytokine Conjugate |
| EP2328620A2 (de) | 2008-07-31 | 2011-06-08 | Alma Mater Studiorum - Università di Bologna | Aktive teilchen für bioanalytische anwendungen und verfahren zu ihrer herstellung |
| EP2444101A1 (de) * | 2010-10-21 | 2012-04-25 | Universitätsklinikum Freiburg | Selektives Targeting der CD40L/Mac-1-Interaktion mit kleinen Peptidinhibitoren und seine Verwendung zur Behandlung von Entzündungen und Atherogenese |
| CU23950B1 (es) * | 2011-03-21 | 2013-10-29 | Ct De Ingeniería Genética Y Biotecnología | Péptidos cíclicos con actividad antineoplásica y antiangiogénica |
| ES2723885T3 (es) | 2012-07-19 | 2019-09-03 | Daiichi Sankyo Co Ltd | Anticuerpos anti-Siglec-15 |
| WO2014037332A1 (en) | 2012-09-04 | 2014-03-13 | Università Degli Studi Di Torino | Inhibitors of alpha6 integrin/e-cadherin complex and their therapeutic and diagnostic use in cancer |
| EP2703005A1 (de) | 2012-09-04 | 2014-03-05 | Università Degli Studi Di Torino | Hemmer des Alpha-6-Integrin/E-Cadherinkomplexes |
| WO2014102312A2 (en) * | 2012-12-28 | 2014-07-03 | Life Sciences Research Partners Vzw | Minimally toxic prodrugs |
| JP6496840B2 (ja) * | 2015-04-27 | 2019-04-10 | マッカイ メモリアル ホスピタルＭａｃｋａｙ Ｍｅｍｏｒｉａｌ Ｈｏｓｐｉｔａｌ | 血管新生に関連する疾患及び／又は病状を治療するための短い合成ペプチド |
| CN112724258A (zh) * | 2019-10-29 | 2021-04-30 | 深圳市第二人民医院 | 靶向杀死癌细胞的复合多肽分子及其制备方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5877243A (en) * | 1997-05-05 | 1999-03-02 | Icet, Inc. | Encrustation and bacterial resistant coatings for medical applications |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US6703491B1 (en) * | 1999-03-17 | 2004-03-09 | Exelixis, Inc. | Drosophila sequences |
| US7834146B2 (en) * | 2000-05-08 | 2010-11-16 | Monsanto Technology Llc | Recombinant polypeptides associated with plants |
| CA2481231A1 (en) * | 2002-04-05 | 2003-10-23 | University Of Utah Research Foundation | Colon tumor specific binding peptides |
| WO2004093804A2 (en) * | 2003-04-18 | 2004-11-04 | Five Prime Therapeutics, Inc. | Human polypeptides encoded by polynucleotides and methods of their use |
| JP3944577B2 (ja) * | 2003-04-21 | 2007-07-11 | 独立行政法人産業技術総合研究所 | Ｒｈｏｄｏｃｏｃｃｕｓ属細菌における組換えタンパク質を生産する方法 |
| AU2005321630A1 (en) * | 2004-07-02 | 2006-07-06 | Metanomics Gmbh | Process for the production of fine chemicals |
| JP5167155B2 (ja) * | 2006-03-09 | 2013-03-21 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法 |
| AU2007250461A1 (en) * | 2006-05-17 | 2007-11-22 | Dairy Australia Limited | Polypeptides and polynucleotides encoding the same |
-
2006
- 2006-11-30 IT IT000852A patent/ITTO20060852A1/it unknown
-
2007
- 2007-11-30 EP EP07856330A patent/EP2121742B1/de not_active Not-in-force
- 2007-11-30 WO PCT/EP2007/010428 patent/WO2008064910A2/en not_active Ceased
- 2007-11-30 AT AT07856330T patent/ATE509949T1/de not_active IP Right Cessation
- 2007-11-30 US US12/516,896 patent/US8779092B2/en not_active Expired - Fee Related
- 2007-11-30 JP JP2009538647A patent/JP2010510785A/ja active Pending
- 2007-11-30 CA CA002670532A patent/CA2670532A1/en not_active Abandoned
- 2007-11-30 AU AU2007324808A patent/AU2007324808B2/en not_active Ceased
- 2007-11-30 ES ES07856330T patent/ES2363044T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2363044T3 (es) | 2011-07-19 |
| US20100041614A1 (en) | 2010-02-18 |
| WO2008064910A2 (en) | 2008-06-05 |
| EP2121742A2 (de) | 2009-11-25 |
| US20100210563A2 (en) | 2010-08-19 |
| AU2007324808B2 (en) | 2012-04-26 |
| US8779092B2 (en) | 2014-07-15 |
| CA2670532A1 (en) | 2008-06-05 |
| WO2008064910A3 (en) | 2008-11-13 |
| AU2007324808A1 (en) | 2008-06-05 |
| WO2008064910A9 (en) | 2009-05-14 |
| US20110294743A9 (en) | 2011-12-01 |
| EP2121742B1 (de) | 2011-05-18 |
| JP2010510785A (ja) | 2010-04-08 |
| ITTO20060852A1 (it) | 2008-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE509949T1 (de) | Metastasisch spezifische peptide und ihre diagnostischen und therapeutischen anwendungen | |
| CY1119892T1 (el) | Φορεις και αλληλουχιες για την αγωγη ασθενειων | |
| CY1118038T1 (el) | Λυοφιλισμενες φαρμακοτεχνικες μορφες θεραπευτικου πεπτισωματος | |
| UA113609C2 (xx) | Антигензв'язуючий білок, який зв'язує людський il-23 | |
| MX2009008430A (es) | Anticuerpos anti-robo4 y sus usos. | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| WO2008140812A3 (en) | Compositions and methods comprising klk3, psca, or folh1 antigen | |
| ATE528989T1 (de) | Kristalline feste rasagilin-base | |
| EA201001883A1 (ru) | Мутанты fgf21 и их применение | |
| ATE440117T1 (de) | Polymermicellen für die arzneistoffzufuhr | |
| MY150226A (en) | Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use | |
| EP2568996A4 (de) | Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen | |
| GT201200189A (es) | Antagonistas de pcsk9 | |
| CY1117328T1 (el) | Διαδικασια για την παρασκευη πολυσιαλικου οξεος υψηλης καθαρiοτητας | |
| EA201100268A1 (ru) | Вакцина | |
| MA32349B1 (fr) | Antagonistes de la voie hedgehog a base de phtalazines disubstituees | |
| EP2438090A4 (de) | Aminosäuresequenzen zur erhöhung der löslichkeit eines peptidkonjugats | |
| ATE404225T1 (de) | Radiofluorierte peptide | |
| CY1114023T1 (el) | Διυποκατεστημενης φθαλαζινης ανταγωνιστες σηματοδοτικης οδου hedgehog | |
| MX2009013682A (es) | Enlazador de fmoc polimerico hidrolizable. | |
| WO2009125409A3 (en) | Fatty acid amides and uses thereof | |
| ATE549353T1 (de) | Aktive varianten des il-18 bindenden proteins und dessen medizinische verwendungen | |
| EA200600404A1 (ru) | Пероральные препаративные формы кладрибина | |
| BRPI0906044A2 (pt) | "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas" | |
| ATE552832T1 (de) | Antidepressivum-propharmaka |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |